Pembrolizumab (Keytruda®) for colorectal cancer. HTA ID: 21002

Assessment Status NCPE Assessment Process Complete
HTA ID 21002
Drug Pembrolizumab
Brand Keytruda®
Indication Is indicated as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
Assessment Process
Rapid review commissioned 08/02/2021
Rapid review completed 03/03/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2021
Pre-submission consultation with Applicant 21/04/2021
Full submission received from Applicant 21/01/2022
Preliminary review sent to Applicant 10/06/2022
NCPE assessment re-commenced 08/07/2022
Factual accuracy sent to Applicant 07/09/2022
NCPE assessment re-commenced 19/09/2022
NCPE assessment completed 13/10/2022
NCPE assessment outcome The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

The HSE has approved reimbursement following confidential price negotiations April 2023.